Baseline characteristics.
| Cohort A (MSI-H) | Cohort B (MSS) | |
|---|---|---|
| Characteristics | (n = 10, %) | (n = 40, %) |
| Median age, years (range) | 53 (30–77) | 63 (25–79) |
| Sex | ||
| Male | 5 (50.0) | 17 (42.5) |
| Female | 5 (50.0) | 23 (57.5) |
| ECOG PS | ||
| 0 | 10 (100) | 34 (85.0) |
| 1 | 0 (0) | 6 (15.0) |
| Primary site | ||
| Right-sided colon | 10 (100) | 27 (67.5) |
| Left-sided colon | 0 (0) | 13 (32.5) |
| Metastatic organ | ||
| Liver | 2 (20.0) | 28 (70.0) |
| Lung | 2 (20.0) | 29 (72.5) |
| Lymph node | 7 (70.0) | 17 (42.5) |
| Peritoneum | 7 (70.0) | 12 (30.0) |
| Number of prior chemotherapy | ||
| ≤2 | 6 (60.0) | 12 (30.0) |
| ≥3 | 4 (40.0) | 28 (70.0) |
| Prior regimens | ||
| Fluoropyrimidine | 10 (100) | 40 (100) |
| Oxaliplatin | 10 (100) | 40 (100) |
| Irinotecan | 10 (100) | 40 (100) |
| Angiogenesis inhibitor | 9 (90.0) | 40 (100) |
| Anti-EGFR inhibitor | 2 (20.0) | 17 (42.5) |
| Regorafenib | 1 (10.0) | 17 (42.5) |
| TAS-102 | 0 (0) | 23 (57.5) |
| RAS status | ||
| Wild-type | 5 (50.0) | 14 (35.0) |
| Mutant | 5 (50.0) | 25 (62.5) |
| Unknown | 0 (0) | 1 (2.5) |
| BRAF V600E status | ||
| Wild-type | 5 (50.0) | 28 (70.0) |
| Mutant | 2 (20.0) | 2 (5.0) |
| Unknown | 3 (30.0) | 10 (25.0) |
| MSI or MMR status | ||
| MSI-high or MMR-deficient | 10 (100) | 0 (0) |
| MSS or MMR-proficient | 0 (0) | 40 (100) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.